A torn ACL, the tiny band of tough connective tissue in the center of the knee, has marked the downfall of many a football star. Remember the running backs Terrell Davis of the Denver Broncos and Jamal Anderson of the Atlanta Falcons?
On Monday, a privately held biotech startup in Boston said it has raised $22.5 million to continue developing its new treatment for the often devastating injury. Among the investors: the union that represents National Football League players.
Dr. Martha Murray, the founder of MIACH Orthopaedics Inc. and an orthopedic surgeon in sports medicine at Boston Children’s Hospital, said the new technology “has the potential to transform connective tissue repair.”
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect